Stocktoria

Rezolute, Inc. RZLT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2011-12-23 · LEI

Rezolute, Inc. financials (annual)

Revenue
2017201820192020202120222023202420252026
Net income
-$20.3M -$29.9M -$30.4M -$20.3M -$20.9M -$41.1M -$51.8M -$68.5M -$74.4M -$77.6M 2017201820192020202120222023202420252026
Free cash flow
-$14.1M -$15.4M -$24.2M -$44.6M 2017201820192020202120222023202420252026

Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).

MetricFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
R&D expense$53.8M$61.5M$55.7M$43.8M$32.5M$15.0M$14.4M$19.1M$17.3M$12.1M
Operating income-$83.0M-$79.9M-$70.4M-$56.0M-$41.8M-$22.9M-$20.5M-$25.9M-$28.7M-$20.3M
Interest expense—————$375,000$0$5.0M$689,000$1,595
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$77.6M-$74.4M-$68.5M-$51.8M-$41.1M-$20.9M-$20.3M-$30.4M-$29.9M-$20.3M
EPS (diluted)$-0.75$-0.98$-1.33$-1.01$-2.32$-2.72————
Operating cash flow-$64.6M-$69.1M-$57.4M-$44.5M-$39.6M-$20.4M-$24.2M-$15.3M-$14.1M-$13.3M
Free cash flow———-$44.6M——-$24.2M-$15.4M-$14.1M—
Cash & equivalents$10.6M$94.1M$70.4M$16.0M$150.4M$41.0M$77.4M$37.6M$1.6M—
Total assets$112.8M$175.5M$132.7M$123.7M$152.4M$42.6M$11.0M$12.3M$2.5M$10.6M
Total liabilities$12.2M$13.4M$11.7M$7.5M$2.9M$16.5M$3.6M$10.5M$6.5M$2.1M
Shareholders' equity$100.7M$162.1M$121.0M$116.2M$149.5M$26.1M$7.4M$1.8M-$4.0M$8.5M

Computed from company filings · US · as of 2026-06-30. Facts plus Stocktoria's own computed scores — not investment advice.